Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 200000
- Registration Number
- NCT02636192
Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone
Phase 1
Completed
- Conditions
- AntipsychoticImmunoassay
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 81
- Registration Number
- NCT02634463
Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer
Phase 1
Completed
- Conditions
- Prostatic Neoplasms, Castration-Resistant
- Interventions
- Biological: JNJ-64041809 (Cohort 1A and 1B)Biological: JNJ-64041809 (Cohort 2A and 2B)
- First Posted Date
- 2015-12-09
- Last Posted Date
- 2019-08-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02625857
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55375515 in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: JNJ-55375515Drug: Placebo
- First Posted Date
- 2015-12-07
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 175
- Registration Number
- NCT02623491
A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT02617810
Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 56
- Registration Number
- NCT02617758
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Phase 1
Active, not recruiting
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 751
- Registration Number
- NCT02609776
A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus
Phase 1
Completed
- Conditions
- Systemic Lupus ErythematosusHealthy
- Interventions
- Drug: JNJ-55920839Drug: Placebo
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2019-03-14
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 72
- Registration Number
- NCT02609789
A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 24
- Registration Number
- NCT02611505
A Pharmacokinetic Interaction Study Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin in Healthy Participants
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 32
- Registration Number
- NCT02611518
© Copyright 2025. All Rights Reserved by MedPath